Core Viewpoint - Fosun Pharma's subsidiary, Gismed (Wuhan) Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for the drug registration application of Cisplatin Injection, which is intended for the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer [1] Group 1: Drug Development and Financials - The drug is independently developed by the group and has seen a cumulative R&D investment of approximately RMB 4.69 million (unaudited) as of January 2026 [1] - According to the latest data from IQVIA CHPA, the sales revenue of Cisplatin Injection in mainland China (excluding Hong Kong, Macau, and Taiwan) is projected to be around RMB 165 million in 2024 [1]

Core Viewpoint - Fosun Pharma's subsidiary, Jinzhou Aohong Pharmaceutical, has received acceptance for its drug registration application for Mivacurium Injection from the National Medical Products Administration, targeting anesthesia induction and short-term surgical anesthesia [1] Group 1 - The drug registration application is classified as a Class 1 chemical drug [1] - The project code for the Mivacurium Injection is ET-26 [1] - The intended indications for the drug include use in anesthesia induction and short-term surgical anesthesia [1]

证券日报网讯2月13日，百花医药（600721）在互动平台回答投资者提问时表示，关于公司2026年的经 营方向，还请关注公司拟定于2026年3月28日，即将披露的公司2025年年度报告。 ...

Core Viewpoint - Tianjin Pharmaceutical Industry announced that its subsidiary, Tianjin Yaohe Pharmaceutical Co., Ltd., has passed the GMP compliance inspection for its eye drop production line, which has a designed capacity of 20 million bottles per year and focuses on the domestic first generic of difluprednate eye drops, projected to achieve global sales of $25 million in 2024 [1]. Group 1 - The production line has a designed capacity of 20 million bottles per year [1]. - The main product is the domestic first generic difluprednate eye drops, used for postoperative anti-inflammatory analgesia [1]. - The projected global sales for 2024 are $25 million [1].

Group 1 - The core viewpoint of the article is that Warner Pharmaceuticals announced its financial results for the fiscal year 2025, showing significant growth in both revenue and net profit [2] - The company achieved an operating revenue of 1,515.59 million yuan, representing a year-on-year increase of 7.26% [2] - The net profit attributable to the parent company was 241.47 million yuan, reflecting a substantial year-on-year growth of 46.95% [2]

2026.02.13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市 场可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和 加拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 投行杰富瑞在一份致客户的报告中表示，她可能不会出现在很多CEO潜在继任者的名单中，她在默克的 业绩没有达到前任高管的水平。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲 ...

Recent Events - Ganli Pharmaceutical's self-developed insulin injection (brand name Ondibta) received marketing approval from the European Commission on January 15, 2026, marking it as the first domestic third-generation insulin to enter the European market, currently in pre-launch preparations including market access and channel layout [1] Company Status - In early 2026, Ganli Pharmaceutical's insulin was approved for sale in Ethiopia, marking its first entry into the sub-Saharan African market; in Latin America, a supply agreement with Brazil was signed for a cumulative order amount of no less than 3 billion yuan, with a fulfillment period of ten years, included in the national medical system's long-term supply framework [2] Product Development Progress - The core pipeline GLP-1 receptor agonist Bofangluretin (biweekly formulation) has entered Phase III clinical trials and is conducting head-to-head trials with Eli Lilly's Tirzepatide and Novo Nordisk's Semaglutide; ultra-long-acting insulin weekly formulation GZR4 and other innovative drugs in the metabolic disease field are also advancing key clinical stages [3] Strategic Advancement - Collaboration with Sandoz is progressing steadily, covering commercialization of Ganli's insulin products (Glycine, Aspart, and Lispro biosimilars) in Europe and specific regions; previously, an exclusive license for Bofangluretin in India was reached with Lupin, and a commercialization agreement was signed with a Latin American company, PC [4] Executive Changes - On January 2026, the company appointed Dr. Wang Qiang, a former executive from Xiansheng Pharmaceutical, as Senior Vice President and Chief Strategy Officer, aiming to strengthen global business development and strategic cooperation, accelerating international expansion [5] Performance and Operating Conditions - The company expects a net profit attributable to shareholders for 2025 to be between 1.1 billion and 1.2 billion yuan, representing a year-on-year growth of 78.96% to 95.23%, primarily benefiting from domestic and international revenue growth and equity transfer gains [6]

2026年2月13日，泽璟制药披露接待调研公告，公司于2月2日至2月10日接待淡水泉、农银汇理、安信基 金、华安基金、建信资产、平安基金等28家机构调研。 调研情况显示，泽璟制药与艾伯维就ZG006达成全球开发及商业化战略合作与许可选择权协议，艾伯维 获大中华区以外地区独家权利，泽璟保留区内权利；泽璟已收到1亿美元首付款，还可获最高6000万美 元近期里程碑及许可选择付款，若选择权行使另有最高10．75亿美元里程碑付款和高个位数到中双位数 阶梯特许权使用费。ZG006正推进单药及联合用药治疗小细胞肺癌、神经内分泌癌等临床试验，包括关 键及III期试验；在晚期小细胞肺癌三线及以上II期剂量优化试验中，10mg每两周一次组确认ORR为53． 3％、mPFS达7．03个月，6个月及12个月OS率分别为83．2％及69．1％；治疗神经内分泌癌推荐剂量 组全人群确认ORR38．5％，DLL3阳性患者达66．7％。 注射用ZG005正推进单药及联合用药治疗肝癌、神经内分泌癌、宫颈癌等试验；二线及以上宫颈癌 20mg／kg Q3W方案确认ORR40．9％、DCR68．2％、mPFS超11个月，联合方案一线宫颈癌及早期肝 癌 ...

2026.02. 13 本文字数：1066，阅读时长大约2分钟 作者 | 第一财经 钱童心 当地时间2月12日，法国制药巨头赛诺菲宣布不再延长现任CEO韩保罗（Paul Hudson）的任期，并任命 65岁的现默克CEO、西班牙人葛丽鹤（Belén Garijo）为CEO。葛丽鹤也将成为赛诺菲史上首位女性 CEO，她将于2026年4月29日集团年度股东大会结束后正式履职。 不过在这一消息公布后，当天赛诺菲股价下跌4.5%。 一位医药行业高管对第一财经记者表示："赛诺菲的新任命让市场不解，这是公司股价下跌的原因，市场 可能期待一位更激进的管理者。" 葛丽鹤于2021年出任默克CEO，她还是法国化妆品巨头欧莱雅的董事会成员。去年，默克集团宣布，葛 丽鹤将按计划在2026年4月底完成任期。在加入默克前，葛丽鹤在赛诺菲工作了15年，当时她是欧洲和加 拿大制药业务副总裁兼执行委员会成员，主要工作包括整合赛诺菲在美国的罕见病药物部门。 即将上任的葛丽鹤预计将面临来自投资者的巨大压力。由于过去几年赛诺菲的药物研发管线停滞不前，加 之美国反疫苗政策的影响，过去一年赛诺菲股价下跌超过25%。 开发新药已被证明是赛诺菲最大的难题 ...

Group 1: Stock Performance - Kangchen Pharmaceutical's stock price has been experiencing a decline, with a range between 39.54 yuan and 44.77 yuan, and a cumulative drop of 2.00% over five days [1] - On February 11, the stock fell by 1.66% with a trading volume of 99.41 million yuan and a net outflow of 9.56 million yuan [1] - The stock continued to decline on February 12, dropping 1.22% to close at 42.26 yuan, with a net outflow of 3.74 million yuan [1] Group 2: Company Developments - The company's R&D pipeline has gained market attention, particularly the KC1086 project, which is an innovative drug for advanced solid tumors, scheduled for a presentation in January 2026 [1] - The KC1036 project, aimed at treating esophageal squamous cell carcinoma, is progressing through Phase III clinical trials, although there have been no recent updates [1] - Kangchen Pharmaceutical conducted a detailed communication with 32 institutions regarding its R&D and operational status at the end of December 2025, but there have been no new records of institutional research in the past week [1] Group 3: Financial Performance - Kangchen Pharmaceutical expects a net profit of 145 million to 175 million yuan for the full year of 2025, representing a year-on-year growth of 243% to 315% [2] - The company's revenue for the first three quarters of 2025 reached 692 million yuan, a year-on-year increase of 7.10%, with a net profit attributable to the parent company of 128 million yuan, up 13.19% [2] - The gross profit margin for the company stands at 90.15%, driven by the performance of its main product "Sulingen" and growth in overseas business [2] Group 4: Market Insights - A report from Bohai Securities noted a 3.14% overall increase in the pharmaceutical and biotechnology sector in January 2026, with heightened attention on innovative drugs and CXO segments due to policy and industry conference influences [2] - However, the report did not provide a specific evaluation of Kangchen Pharmaceutical, and there have been no recent special ratings issued by institutions for the company [2]